Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Pressure on Konstas and Khawaja after Cummins takes all-time screamer Couple's 'wild adventure' crossing the Nullarbor in ...

Discover Marseille, the oldest port city in France and a gem of the Mediterranean. Explore its main tourist spots like the ...

Ginger also understands what it means to be a visible figure in the body-diverse community. Should she win All Stars 10, ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...